Pfizer Inc. (NYSE:PFE) Shares Sold by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 75.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,000 shares of the biopharmaceutical company’s stock after selling 105,000 shares during the period. AlphaCentric Advisors LLC’s holdings in Pfizer were worth $1,013,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Greenwood Capital Associates LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at about $1,473,000. FSM Wealth Advisors LLC raised its position in shares of Pfizer by 24.1% during the 3rd quarter. FSM Wealth Advisors LLC now owns 18,982 shares of the biopharmaceutical company’s stock worth $549,000 after purchasing an additional 3,688 shares during the period. Moloney Securities Asset Management LLC lifted its holdings in shares of Pfizer by 37.8% in the 3rd quarter. Moloney Securities Asset Management LLC now owns 21,086 shares of the biopharmaceutical company’s stock worth $610,000 after purchasing an additional 5,785 shares during the last quarter. Quintet Private Bank Europe S.A. boosted its position in Pfizer by 14.7% during the 3rd quarter. Quintet Private Bank Europe S.A. now owns 358,003 shares of the biopharmaceutical company’s stock valued at $10,361,000 after purchasing an additional 46,016 shares during the period. Finally, PDS Planning Inc grew its stake in Pfizer by 11.5% during the 3rd quarter. PDS Planning Inc now owns 31,446 shares of the biopharmaceutical company’s stock worth $910,000 after buying an additional 3,237 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.2 %

NYSE PFE opened at $27.76 on Tuesday. The company has a market capitalization of $157.31 billion, a PE ratio of 37.51, a price-to-earnings-growth ratio of 0.89 and a beta of 0.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm’s fifty day simple moving average is $29.01 and its 200-day simple moving average is $28.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the business earned ($0.17) EPS. The business’s quarterly revenue was up 31.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.05%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is presently 227.03%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.58.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.